Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | UCM-1336 |
Synonyms | |
Therapy Description |
UCM-1336 is an inhibitor of isoprenylcysteine carboxylmethyltransferase (ICMT), which may result in mislocalization of Ras, decreased Ras activity, and induction of cell death (PMID: 31181882). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
UCM-1336 | UCM1336|UCM 1336 | UCM-1336 is an inhibitor of isoprenylcysteine carboxylmethyltransferase (ICMT), which may result in mislocalization of Ras, decreased Ras activity, and induction of cell death (PMID: 31181882). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61K | acute myeloid leukemia | predicted - sensitive | UCM-1336 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, UCM-1336 treatment inhibited growth of acute myeloid leukemia cells harboring NRAS Q61K in culture, and reduced bone marrow tumor burden and significantly prolonged survival (HR=6.211; p=0.0274) in cell line xenograft models (PMID: 31181882). | 31181882 |
NRAS Q61K | melanoma | predicted - sensitive | UCM-1336 | Preclinical - Cell culture | Actionable | In a preclinical study, UCM-1336 treatment inhibited growth of melanoma cells harboring NRAS Q61K in culture (PMID: 31181882). | 31181882 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|